July 14, 2026

To
The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Plot C-1, Block- G
Bandra Kurla Complex, Bandra (East)
Mumbai – 400051

NSE Scrip: VILINBIO

Sub: Incorporation of Wholly Owned Subsidiaries of M/s Vilin Bio Med Limited ("the Company")

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 of Listing Regulations read with Part A of Schedule III, this is to inform that the Company is under the process of incorporating two (2) Wholly Owned Subsidiaries of the Company with the details of the Object and other disclosures as mentioned in the Annexure – I and Annexure – II and further on application filed by the Company with the Ministry of Corporate Affairs, the Company is in receipt of the following approved names viz "Vilo Speciality Pharma Private Limited" and "Axia Pharma Private Limited" and the Company has also agreed to Subscribe to the Capital of the said Subsidiary Companies.

The details as required under Regulation 30 of the Listing Regulations read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are enclosed herewith as Annexure – I and Annexure – II.

Kindly take the above information on record.

For Vilin Bio Med Limited

YADAMAKANTI MADHU SUDHAN REDDY
Digitally signed by YADAMAKANTI MADHU SUDHAN REDDY
Date: 2026.07.14 18:29:01 +05'30'

Madhusudhan Yadamakanti Reddy
Managing Director
DIN: 02874260

Registered Office: H. No. 8-2-269/S/43, Plot No. 43, 2nd Floor, Sagar Co-op Housing Society Ltd, Road No. 2, Banjara Hills Khairatabad, Hyderabad – 500034
Manufacturing Unit: Unit-II, Khasra No. 85, Madhopur Village, Roorkee, Haridwar – 247667
Tel No: 040- 79618843 CIN: L24230TG2005PLC046689 GST: 36AACCV1433D1ZR
E-mail: cs@vilinBiomed.co.in Website: www.vilinBio.com

Annexure – I

Sl No	Particulars	Disclosures
1	Name of the Target Company, details in brief such as size, Turnover, etc.	Name: Vilo Speciality Pharma Private Limited ("VSPPL") Proposed Authorised Capital: Rs.10,00,000/- (Rupees Ten Lakhs) comprising of 1,00,000 (One Lakh) Equity Shares of Rs.10/- (Rupees Ten) each. Size/Turnover: Not Applicable (yet to commence business operations)
2	Whether the acquisition would fall within Related Party Transaction(s) and whether the Promoter / Promoter Group / Group Companies have any interest in the Entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "Arm's Length"	Not Applicable
3	Industry to which the Entity being acquired belongs	Pharmaceutical Industry
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of Target Entity, if its business is outside the main line of business of the Listed Entity)	<u>Object of Newly Incorporated Company:</u> 1. To carry on the business of Marketing, Promotion, Branding, Distribution, Wholesale, Trading, Import, Export, Buying and Selling of Oncology Pharmaceutical Products, Oncology Medicines, Specialty Pharmaceutical Products, Healthcare Products and allied Pharmaceutical Formulations. 2. To provide Product Management, Sales Promotion, Medical Marketing, Advertising, Business Development, Market Research, Consultancy and other Business Support Services in relation to Oncology Pharmaceutical, Bio-technology, Healthcare and Medical Products. 3. To undertake or arrange for the Manufacture, Processing, Packaging, Labelling, Distribution and Supply of Oncology Pharmaceutical Products and Healthcare Products through its own facilities or through third parties.

5	Brief details of any Governmental or Regulatory Approvals required for the acquisition	Not Applicable
6	Indicative time period for completion of the acquisition	Not Applicable
7	Nature of Consideration – whether Cash Consideration or Share Swap and details of the same	Not Applicable
8	Cost of acquisition or the price at which the Shares are acquired	Not Applicable
9	Percentage of Shareholding/ Control acquired and/or Number of Shares acquired	100% - Proposed to be incorporated as Wholly Owned Subsidiary.
10	Brief background about the Entity acquired in terms of Products / Line of Business acquired, Date of Incorporation, History of last 3 years, Turnover, country in which the acquired Entity has presence and any other significant information (in brief)	Product/line of Business: "Manufacturing, Marketing, and Distribution of Pharmaceutical Products, and Oncology Products." Date of Incorporation: Not Applicable History/Turnover: Not Applicable Country of Incorporation: India

VILIN BIO MED
One-Stop Hub for all Pharmaceutical Solutions

Annexure – II

Sl No	Particulars	Disclosures
1	Name of the Target Company, details in brief such as size, Turnover, etc.	Name: Axia Pharma Private Limited ("APPL") Proposed Authorised Capital: Rs.10,00,000/- (Rupees Ten Lakhs) comprising of 1,00,000 (One Lakh) Equity Shares of Rs.10/- (Rupees Ten) each. Size/Turnover: Not Applicable (yet to commence business operations)
2	Whether the acquisition would fall within Related Party Transaction(s) and whether the Promoter / Promoter Group / Group Companies have any interest in the Entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "Arm's Length"	Not Applicable
3	Industry to which the Entity being acquired belongs	Pharmaceutical Industry
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of Target Entity, if its business is outside the main line of business of the Listed Entity)	<u>Object of Newly Incorporated Company:</u> 1. To carry on the business of Marketing, Promotion, Branding, Distribution, Wholesale, Trading, Import, Export, Buying and Selling of Pharmaceutical Products, Medicines, Medicinal Substances, Active Pharmaceutical Ingredients (API), Anti-biotics, Endocrine Products, Vitamins, Opium Derivatives, Sulpha Drugs, Serums, Plasmas, Salicylic Acid and Salts and Esters, Glycosides, Vegetable Alkaloids, Chemically Pure Sugars, Generic Pharmaceutical Products, Healthcare Products and Allied Pharmaceutical Preparations, subject to applicable laws. 2. To provide Product Management, Sales Promotion, Generic Pharmaceutical Marketing, Business Development, Advertising, Market Research, Consultancy and other Business Support Services in relation to Pharmaceutical, Bio-technology and Healthcare Products.

Registered Office: H. No. 8-2-269/S/43, Plot No. 43, 2nd Floor, Sagar Co-op Housing Society Ltd, Road No. 2, Banjara Hills Khairatabad, Hyderabad – 500034
Manufacturing Unit: Unit-II, Khasra No. 85, Madhopur Village, Roorkee, Haridwar – 247667
Tel No: 040- 79618843 CIN: L24230TG2005PLC046689 GST: 36AACCV1433D1ZR
E-mail: cs@vilinBiomed.co.in Website: www.vilinBio.com

5	Brief details of any Governmental or Regulatory Approvals required for the Acquisition	Not Applicable
6	Indicative time period for completion of the Acquisition	Not Applicable
7	Nature of Consideration – whether Cash Consideration or Share Swap and details of the same	Not Applicable
8	Cost of acquisition or the price at which the Shares are acquired	Not Applicable
9	Percentage of Shareholding/ Control acquired and/or Number of Shares acquired	100% - Proposed to be incorporated as Wholly Owned Subsidiary.
10	Brief background about the Entity acquired in terms of Products / Line of Business acquired, Date of Incorporation, History of last 3 years, Turnover, country in which the acquired Entity has presence and any other significant information (in brief)	Product/line of Business: "Manufacturing, Marketing, and Distribution of Pharmaceutical and Generic Products." Date of Incorporation: Not Applicable History/Turnover: Not Applicable Country of Incorporation: India